Thirty‐day mortality after systemic anticancer treatment as a real‐world, quality‐of‐care indicator: the Northland experience

Ang, Edmond; Newton, Los Vincent

doi:10.1111/imj.13618

Cited by 12 publications

(16 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 30-day mortality rate reported globally prior to the COVID-19 pandemic ranged from 2.5% to 5.12%. [14][15][16][17] Similarly, in our study, the 30-day mortality rate was 5.1%. To the best of our knowledge, no comparable study from Saudi Arabia addressing early mortality and morbidity post-chemotherapy in cancer patients is available.…”

Section: Resultssupporting

confidence: 73%

Morbidity and Mortality among Cancer Patients Receiving Anticancer Treatment during the COVID-19 Pandemic: A Single Tertiary Center Experience

Al‐Hajeili¹,

Samargandy²

2021

Pharmacophore

View full text Add to dashboard Cite

Since the beginning of 2020, the emergence of the COVID-19 pandemic has limited many aspects of health care delivery. These limitations have affected cancer patients in various ways, raising concerns about worsening morbidity and mortality among this special population. No studies have assessed the impact of the pandemic on the short-term morbidity and mortality among cancer patients. This study aimed to determine the effect of the pandemic on the early clinical outcomes in cancer patients receiving anticancer treatment in Saudi Arabia during the pandemic period. This included adult patients with solid or hematological tumors undergoing anticancer therapy. We collected data on patient demographics, health status, type of treatment, and morbidity and mortality outcomes. We performed univariate and multivariate analyses to identify possible associations with each variable, including the COVID-19 test results. The mean age of the patients was 52.32 years, and 69.9% of the population were women. Of the patients, 64.1% were administered curative therapy. The 30-day morbidity and mortality rates were 19.2% and 5.1%, respectively. Ten patients (2.5%) developed COVID-19 during the study period, of whom three died. The mortality rate was 30% and 4.4% in cancer patients with and without COVID-19, respectively. The Eastern Cooperative Oncology Group performance status was associated with higher 30-day morbidity (odds ratio: 8.48, P < .001) and mortality (odds ratio: 3.86, P < .001). The mortality rate in cancer patients receiving anticancer treatment during the COVID-19 pandemic was similar to that reported in the literature preceding the pandemic.

show abstract

Section: Resultssupporting

confidence: 73%

Morbidity and Mortality among Cancer Patients Receiving Anticancer Treatment during the COVID-19 Pandemic: A Single Tertiary Center Experience

Al‐Hajeili¹,

Samargandy²

2021

Pharmacophore

View full text Add to dashboard Cite

show abstract

“…This mortality rate, which could be established as the national standard for Saudi Arabia, was found to be lower than that of previous reports from cancer centers in Australia, England, and New Zealand, which included outpatient systemic chemotherapy for adults with solid and hematologic tumors and reported 30-day mortality rates of 5.6% for Australia, 4% for England, and 5.2% for New Zealand. [18][19][20][21] This could be explained by the younger population in our study than in previous studies.…”

Section: Discussioncontrasting

confidence: 63%

<p>Thirty-Day Mortality After Curative and Palliative Anti-Cancer Treatment: Data Interpretation and Lessons for Clinical Implementation</p>

Tashkandi

Basulaiman

Alghareeb

et al. 2020

CMAR

View full text Add to dashboard Cite

Purpose: Despite advancements in cancer therapeutics, mortality and morbidity due to anticancer treatments still occur but are not frequently reported. We aimed to report the 30-day mortality and morbidity of all curative and palliative anti-cancer treatments. Patients and Methods: Adults with solid and hematological malignancies from two large cancer centers in Saudi Arabia, irrespective of the cancer stage and treatment type, were included in this retrospective observational study. Results: Between December 1, 2019 and February 29, 2020, 1694 patients from King Abdullah Medical City in Makkah and King Fahad Medical City in Riyadh were included in the study. Among them, 77.5% were younger than 65 years of age; 72.8% were female; the prevalence of obesity, diabetes, and hypertension was 35%, 34%, and 28%, respectively; and 66.5% of patients had breast and gastrointestinal cancers. Fifty-nine (3.5%) patients died within 30 days of receiving anti-cancer treatment. Of them, 9 (0.3%) were treated with curative intent, and 50 (3%) were treated with palliative intent. Conclusion: Our results emphasize the need to address preventable metabolic changes and implement innovative, predictive, preventive, and personalized medicine (PPPM) approaches focusing on patient profiles. Reporting the 30-day outcomes of all anti-cancer treatments will also allow the identification of factors underlying mortality and morbidity and lead to an improvement in oncological outcomes via innovative programs designed to improve clinical decision-making.

show abstract

“…El conocer la mortalidad a 30 días posterior a la administración de quimioterapia sistémica permite auditar el quehacer de las unidades de oncología y compararlos con los estándares de referencia internacionales 8,9 . Nuestro estudio demostró una baja tasa de mortalidad a 30 días posterior a la administración de quimioterapia (2,46%), el que resulta favorable al compararlo con datos publicados donde la cifra de referencia es 5% 10 .…”

Section: Discussionunclassified

“…Un estudio poblacional realizado en Inglaterra (n = 43.409) que incluyó sólo a pacientes con cáncer de mama y pulmón que recibieron tratamiento durante el año 2014, reportó una mortalidad a 30 días asociada a quimioterapia de < 1% para pacientes con cáncer de mama tratados con intención curativa y de 10% para pacientes con cáncer de pulmón (todos los subtipos) tratados con intención paliativa 5 . Reportes realizados en centros oncológicos en Australia, Inglaterra y Nueva Zelandia que incluyeron a todos los pacientes adultos que recibieron quimioterapia sistémica ambulatoria tanto para tumores sólidos como hematológicos, reportaron tasas de mortalidad a 30 días de 5,6%, 4% y 5,17% respectivamente [6][7][8] .…”

unclassified

See 1 more Smart Citation

Mortalidad a 30 días posterior a la administración de quimioterapia sistémica en una unidad oncológica regional

2019

Rev. méd. Chile

View full text Add to dashboard Cite

Mortality within 30 days of receiving systemic chemotherapy at a regional oncology unit Background: The use of systemic chemotherapy has survival and palliation benefits in oncological patients. Mortality at 30 days after the administration of systemic chemotherapy is considered as a quality and safety indicator of oncological patient care. The international mortality threshold is 5%, which is the figure used to compare institutions. Aim: To assess mortality at 30 days after the administration of ambulatory systemic chemotherapy in a regional referral center in adult cancer patients. Material and Methods: Retrospective observational study of patients receiving ambulatory systemic chemotherapy in the oncology service of a regional public hospital during 2018. The 30-day mortality rate was calculated. Demographic characteristics, baseline disease and the treatment received were recorded. Results: During the study period, 690 patients received ambulatory systemic chemotherapy. Chemotherapy was palliative in 76% of patients and 53% received a first line treatment. Seventeen (2.5%) died within 30 days of treatment administration. Nine deaths (52.9%) were definitely related to treatment and sepsis was the most frequent cause. Conclusions: Our mortality rates are similar to international data. This type of audit reviews local outcomes and identifies factors contributing to mortality aiming to improve standards of care.

show abstract

Thirty‐day mortality after systemic anticancer treatment as a real‐world, quality‐of‐care indicator: the Northland experience

Abstract: Thirty-day mortality rates were comparable to studies from larger institutions. We demonstrated the feasibility of this index for auditing practice in smaller oncology units over a longer timeframe.

Cited by 12 publications

References 17 publications

Morbidity and Mortality among Cancer Patients Receiving Anticancer Treatment during the COVID-19 Pandemic: A Single Tertiary Center Experience

Morbidity and Mortality among Cancer Patients Receiving Anticancer Treatment during the COVID-19 Pandemic: A Single Tertiary Center Experience

<p>Thirty-Day Mortality After Curative and Palliative Anti-Cancer Treatment: Data Interpretation and Lessons for Clinical Implementation</p>

Mortalidad a 30 días posterior a la administración de quimioterapia sistémica en una unidad oncológica regional

Contact Info

Product

Resources

About